# Hypercoagulability in Pulmonary Tuberculosis: Reduced Protein C and Free Protein S Predict Pulmonary Embolism—Evidence from a Prospective Romanian Cohort

**Authors:** Denisa Maria Mitroi, Silviu Gabriel Vlasceanu, Ovidiu Mircea Zlatian, Mihai Olteanu, Oana Maria Catană, Radu Razvan Mititelu, Anca Lelia Riza, Georgiana Camen, Viorel Biciușcă, Ramona Cioboată

PMC · DOI: 10.3390/jcm15051903 · Journal of Clinical Medicine · 2026-03-02

## TL;DR

This study shows that people with active pulmonary tuberculosis have lower levels of natural anticoagulants, which are linked to more severe disease and blood clots.

## Contribution

The study identifies protein C and free protein S as novel biomarkers for predicting disease severity and complications in pulmonary tuberculosis.

## Key findings

- TB patients had significantly lower protein C and free protein S levels compared to controls.
- Lower baseline protein C and free protein S predicted higher bacillary burden and delayed microbiological clearance.
- Reduced anticoagulant levels were associated with more residual CT abnormalities and increased risk of pulmonary embolism.

## Abstract

Background/Objectives: Pulmonary tuberculosis (TB) is accompanied by inflammation-driven hypercoagulability and increased venous thromboembolism risk. We investigated whether the natural anticoagulants protein C and free protein S are reduced in active TB and whether baseline levels are associated with bacillary burden, treatment response, CT evolution, and pulmonary embolism (PE). Methods: We conducted a prospective cohort study in Romania, including 63 adults with newly diagnosed, bacteriologically confirmed, drug-susceptible pulmonary TB and 30 TB-free controls (October 2024–December 2025). Venous blood was collected at baseline (before anti-TB therapy) and at 6 months to quantify inflammatory and coagulation parameters, protein C, and free protein S. Sputum AFB smear was assessed at baseline, 2 months, and 6 months; chest CT was performed at baseline and 6 months. Propensity score matching (age, sex, BMI, smoking) and multivariable regression were used to account for confounding. Logistic regression and ROC analyses evaluated the prediction of BK persistence. Results: Compared with controls, TB patients had substantially lower baseline protein C and free protein S levels, and higher D-dimer levels (all p < 0.001). In matched multivariable models, TB status remained independently associated with lower baseline natural anticoagulant levels. Lower baseline protein C and free protein S clustered with higher inflammatory markers and higher bacillary burden, and independently predicted BK persistence at 2 and 6 months (OR per 1%-point increase ~0.93–0.95 for protein C and ~0.92–0.94 for free protein S; all p < 0.001). Discrimination for BK persistence was high (AUCs ~0.88–0.89). Lower baseline levels of natural anticoagulants were also associated with greater residual CT abnormalities at 6 months. PE cases had significantly lower protein C and free protein S than PE-free patients. Conclusions: Active pulmonary TB is associated with marked depletion of protein C and free protein S. Baseline reductions identify patients with higher inflammatory/coagulation activation, higher bacillary burden, delayed microbiological clearance, more residual CT disease, and PE, supporting their potential role as adjunct risk-stratification biomarkers.

## Linked entities

- **Diseases:** pulmonary tuberculosis (MONDO:0006052), venous thromboembolism (MONDO:0005399), pulmonary embolism (MONDO:0005279)

## Full-text entities

- **Genes:** PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}
- **Diseases:** coagulation (MESH:D001778), PE (MESH:D011655), Pulmonary Tuberculosis (MESH:D014397), Hypercoagulability (MESH:D019851), inflammation (MESH:D007249), TB (MESH:D014376), CT abnormalities (MESH:D000014), venous thromboembolism (MESH:D054556)
- **Chemicals:** natural (-), BK (MESH:D001603)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12985418/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12985418/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12985418/full.md

---
Source: https://tomesphere.com/paper/PMC12985418